NeoCura

Apr 19, 2024

Brought to you by XH-001 is under clinical development by NeoCura Bio-Medical Technology and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XH-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here. Smarter leaders trust GlobalData GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. XH-001 overview XH-001 is under development for the treatment advanced solid tumors. It is an mRNA-based tumor neoantigen vaccine and is being developed based on NeoCura Ag, an artificial intelligence (AI) technology. See Also: NeoCura Bio-Medical Technology overview NeoCura Bio-Medical Technology (NeoCura) formerly Shenzhen NeoCura Biotechnology (NeoCura) is an developer of an artificial intelligence (AI) medical platform intended to improve the precision diagnosis and treatment of tumor. NeoCura is headquartered in Shenzhen, Guangdong, China. For a complete picture of XH-001’s drug-specific PTSR and LoA scores, buy the report here. This content was updated on 18 March 2024 Sign up for our daily news round-up! Give your business an edge with our leading industry insights. The gold standard of business intelligence. Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. GlobalData , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center . Share this article Your corporate email address * Pharma Technology Focus : Pharmaceutical Technology Focus (monthly) Thematic Take (monthly) I consent to Verdict Media Limited collecting my details provided via this form in accordance with Privacy Policy Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Thank you for subscribing close